NovaDel Pharma to Present at Biotech Showcase 2011

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- NovaDel Pharma Inc. (OTCQB: NVDL) today announced that Steven Ratoff, Chairman, President and Chief Executive Officer, will present at the Biotech Showcase 2011 in San Francisco on Tuesday, January 11, 2011 at 11:15 a.m. PT. Company management will be available for meetings at the conference.

The Biotech Showcase is being held at the Parc 55 Wyndham San Francisco Union Square Hotel. In its third year, the Biotech Showcase™ provides private and public life science companies the opportunity to present to an audience of investors and business development executives.


NovaDel Pharma Inc. is a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed pharmaceutical products. The Company’s patented oral spray drug delivery technology seeks to improve the efficacy and safety of existing prescription pharmaceuticals, as well as patient compliance and patient convenience. NovaDel has two products that have been approved by the FDA: NitroMist® for the treatment of angina, and Zolpimist™ for the treatment of insomnia. NovaDel’s current product candidates target erectile dysfunction, nausea, migraine headache and disorders of the central nervous system. NovaDel plans to develop these and other products independently and through collaborative arrangements with pharmaceutical and biotechnology companies. To find out more about NovaDel Pharma Inc. (OTCQB: NVDL), visit our website at


NovaDel Pharma Inc.
Steven B. Ratoff, 908-203-4640
Chairman, President and Chief Executive Officer
[email protected]

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical



Suggested Articles

The analysis found Nexvax2 was no better than placebo at protecting patients from gluten, prompting the Arch-backed biotech to stop the study.

Johns Hopkins scientists found that misfolded alpha-synuclein protein can travel from the gut and drive Parkinson's disease.

The financing sets Sanifit up to take its lead drug through phase 3 while exploring its potential in other progressive vascular calcification disorders.